Home > Archive > 2013 >

Volume 32, Number 4 (November/December)

American Diabetes Association Guideline Compliance in the Alabama School System (pages 6–22)

Jessica Skelley, Pharm.D., David R. Luthin, Ph.D., Thomas W. Woolley, Ph.D., Jack Berry, Ph.D., Jason Skelley, M.D., Charles D. Sands IV, Ph.D., Ali Lloyd, Pharm.D. Candidate, 2015, and Ashley Waddell, Pharm.D Candidate, 2015

In this article, the authors address complying with the American Diabetes Association guidelines in a school setting. The article describes how the public schools in Alabama are implementing the guidelines and what resources would improve this implementation. It also compares how other states have dealt with the issue and makes recommendations for future research.
Professional guidelines

Diagnosing the ‘Disease’ of Central Obesity (pages 23–27)

Tamara Shan and Samir Desai, M.D.

Recent modifications in national guidelines for diagnosing metabolic syndrome reflect the increasing concern that significant visceral or central obesity may be unrecognized in many patient groups. This article reviews these guideline changes and discusses some of the proposed methods of measuring central obesity, focusing on those that can be usefully applied in clinical practice.
Complications and comorbiditiesObesity

Podiatric Diabetology (pages 28–30)

Joseph Alencherry, D.P.M., A.A.C.F.A.S., and Fred DeLucia, D.P.M., A.A.C.F.A.S.

The goal of the therapeutic diabetic shoe program is to prevent development of lower extremity ulcerations that often lead to infections of soft tissues and bone, and eventual amputation. This article outlines how the primary care physician fits into this process.
Complications and comorbiditiesFoot complications

Screening for Type 1 Diabetes (pages 31–33)

Kathleen Wyne, M.D., Ph.D.

Although we do not yet have a simple blood test that can be drawn once to predict the risk of T1DM, the DPT-1 and its successor, the TrialNet NHS, have given us a great deal of information on predicting risk. In this piece, the Medical Editor proposes that the TrialNet NHS continues to provide an opportunity for screening interested high-risk individuals.